Antiproliferative effects of rapamycin and celecoxib in angiosarcoma cell lines

Anticancer Research

Volumn 30, Issue 10, 2010, Pages 4017-4023

  Bundscherer, Annika ^a   Vogt, Thomas ^a   Köhl, Gudrun ^a   Landthaler, Michael ^a   Hafner, Christian ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Angiosarcoma; Celecoxib; COX 2; Endothelial tumour; mTOR; Rapamycin

Indexed keywords

CELECOXIB; RAPAMYCIN;

ANGIOSARCOMA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER PALLIATIVE THERAPY; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SARCOMA CELL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HEMANGIOSARCOMA; HUMANS; MICE; PYRAZOLES; SIROLIMUS; SULFONAMIDES;

EID: 78650255566     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Vogt T: Angiosarcoma. Hautarzt, 2008.
2. Huang J and Mackillop WJ: Increased risk of soft tissue sarcoma after radiotherapy in women with breast carcinoma. Cancer 92: 172-180, 2001.
3. Hodgson NC, Bowen-Wells C, Moffat F, Franceschi D and Avisar E: Angiosarcomas of the breast: a review of 70 cases. Am J Clin Oncol 30: 570-573, 2007.
4. Mendenhall WM, Mendenhall CM, Werning JW, Reith JD and Mendenhall NP: Cutaneous angiosarcoma. Am J Clin Oncol 29: 524-528, 2006.
5. Hafner C, Reichle A and Vogt T: New indications for established drugs: combined tumor stroma-targeted cancer therapy with PPARgamma agonists, COX-2 inhibitors, mTOR antagonists and metronomic chemotherapy. Curr Cancer Drug Targets 5: 393-419, 2005.
6. Sanborn R and Blanke CD: Cyclooxygenase-2 inhibition in colorectal cancer: boom or bust? Semin Oncol 32: 69-75, 2005.
7. Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB and De Marzo AM: Cyclooxygenases in cancer: progress and perspective. Cancer Lett 275: 1-20, 2004.
8. Schwab JM, Schluesener HJ, Meyermann R and Serhan CN: COX-3 the enzyme and the concept: steps towards highly specialized pathways and precision therapeutics? Prostaglandins Leukot Essent Fatty Acids 69: 339-343, 2003.
9. Vandoros GP, Konstantinopoulos PA, Sotiropoulou-Bonikou G, Kominea A, Papachristou GI, Karamouzis MV, Gkermpesi M, Varakis I and Papavassiliou AG: PPAR-gamma is expressed and NF-kB pathway is activated and correlates positively with COX-2 expression in stromal myofibroblasts surrounding colon adenocarcinomas. J Cancer Res Clin Oncol 132: 76-84, 2006.
10. Kim SJ, Rabbani ZN, Dong F, Vollmer RT, Schreiber EG, Dewhirst MW, Vujaskovic Z and Kelley MJ: Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer. Med Oncol 27: 91-97, 2010.
11. Schmitz KJ, Wohlschlaeger J, Lang H, Sotiropoulos GC, Kaiser GM, Schmid KW and Baba HA: Cyclo-oxygenase-2 overexpression is a feature of early and well-differentiated hepatocellular carcinoma with a favourable prognosis. J Clin Pathol 62: 690-693, 2009.
12. kip1 and cell cycle arrest. Cancer Res 64: 1369-1376, 2004.
13. Cui W, Yu CH and Hu KQ: In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells. Clin Cancer Res 11: 8213-8221, 2005.
14. Patel MI, Subbaramaiah K, Du B, Chang M, Yang P, Newman RA, Cordon-Cardo C, Thaler HT and Dannenberg AJ: Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res 11: 1999-2007, 2005.
15. Kim SH, Song SH, Kim SG, Chun KS, Lim SY, Na HK, Kim JW, Surh YJ, Bang YJ and Song YS: Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-kappaB as a possible target. J Cancer Res Clin Oncol 130: 551-560, 2004.
16. Reichle A, Brass K, Vogt T, Bataille F, Wild P, Berand A, Krause SW and Andreesen R: Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma. Cancer 101: 2247-2256, 2004.
17. Coras B, Hafner C, Reichle A, Hohenleutner U, Szeimies RM, Landthaler M and Vogt T: Antiangiogenic therapy with pioglitazone, rofecoxib, and trofosfamide in a patient with endemic kaposi sarcoma. Arch Dermatol 140: 1504-1507, 2004.
18. Vogt T, Hafner C, Bross K, Bataille F, Jauch KW, Berand A, Landthaler M, Andreesen R and Reichle A: Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors. Cancer 98: 2251-2256, 2003.
19. Gogas H, Polyzos A, Stavrinidis I, Frangia K, Tsoutsos D, Panagiotou P, Markopoulos C, Papadopoulos O, Pectasides D, Mantzourani M, Middleton M, Vaiopoulos G and Fountzilas G: Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol, 2006.
20. Vogt T, McClelland M, Jung B, Popova S, Bogenrieder T, Becker B, Rumpler G, Landthaler M and Stolz W: Progression and NSAID-induced apoptosis in malignant melanomas are independent of cyclooxygenase II. Melanoma Res 11: 587-599, 2001.
21. Huang S and Houghton PJ: Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 3: 371-377, 2003.
22. Vezina C, Kudelski A and Sehgal SN: Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 28: 721-726, 1975.
23. Eng CP, Sehgal SN and Vezina C: Activity of rapamycin (AY-22,989) against transplanted tumors. J Antibiot (Tokyo) 37: 1231-1237, 1984.
24. Douros J and Suffness M: New antitumor substances of natural origin. Cancer Treat Rev 8: 63-87, 1981.
25. Krump-Konvalinkova V, Bittinger F, Olert J, Bräuninger W, Brunner J and Kirkpatrick CJ: Establishment and characterization of an angiosarcoma-derived cell line, AS-M. Endothelium 10: 319-328, 2003.
26. Masuzawa M, Fujimura T, Hamada Y, Fujita Y, Hara H, Nishiyama S, Katsuoka K, Tamauchi H and Sakurai Y: Establishment of a human hemangiosarcoma cell line (ISO-HAS). Int J Cancer 81: 305-308, 1999.
27. Masuzawa M, Fujimura T, Tsubokawa M, Nishiyama S, Katsuoka K, Terada E, Kunita S, Sakaurai Y and Kato H: Establishment of a new murine-phenotypic angiosarcoma cell line (ISOS-1). J Dermatol Sci 16: 91-98, 1998.
28. Bundscherer A, Hafner C, Maisch T, Becker B, Landthaler M and Vogt T: Antiproliferative and proapoptotic effects of rapamycin and celecoxib in malignant melanoma cell lines. Oncol Rep 19: 547-553, 2008.
29. Namba R, Young LJ, Abbey CK, Kim L, Damonte P, Borowsky AD, Qi J, Tepper CG, MacLeod CL, Cardiff RD and Gregg JP: Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ. Clin Cancer Res 12: 2613-2621, 2006.
30. El-Rayes BF, Ali S, Sarkar FH and Philip PA: Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines. Mol Cancer Ther 3: 1421-1426, 2004.
31. Zhou C, Bae-Jump VL, Whang YE, Gehrig PA and Boggess JF: The PTEN tumor suppressor inhibits telomerase activity in endometrial cancer cells by decreasing hTEKT mRNA levels. Gynecol Oncol 101: 305-310, 2006.
32. Zhou C, Gehrig PA, Whang YE and Boggess JF: Rapamycin inhibits telomerase activity by decreasing the KTEKT mRNA level in endometrial cancer cells. Mol Cancer Ther 2: 789-795, 2003.
33. Boffa DJ, Luan F, Thomas D, Yang H, Sharma VK, Lagman M and Suthanthiran M: Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer. Clin Cancer Res 10: 293-300, 2004.
34. DeGraffenried LA, Fulcher L, Friedrichs WE, Grunwald V, Ray RB and Hidalgo M: Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann Oncol 15: 1510-1516, 2004.
35. Tate G, Suzuki T and Mitsuya T: Mutation of the PTEN gene in a human hepatic angiosarcoma. Cancer Genet Cytogenet 178: 160-162, 2007.
36. Dickerson EB, Thomas R, Fosmire SP, Lamerato-Kozicki AR, Bianco SR, Wojcieszyn JW, Breen M, Helfand SC and Modiano JF: Mutations of phosphatase and tensin homolog deleted from chromosome 10 in canine hemangiosarcoma. Vet Pathol 42: 618-632, 2005.
37. Hudes GR, Berkenblit A, Feingold J, Atkins MB, Rini BI and Dutcher J: Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma. Semin Oncol 36(Suppl 3): S26-36, 2009.
38. Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, Laurell A, Offner F, Strahs A, Berkenblit A, Hanushevsky O, Clancy J, Hewes B, Moore L and Coiffier B: Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 27: 3822-3829, 2009.
39. Hartford CM, Desai AA, Janisch L, Karrison T, Rivera VM, Berk L, Loewy JW, Kindler H, Stadler WM, Knowles HL, Bedrosian C and Ratain MJ: A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res 15: 1428-1434, 2009.
40. Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, Ranieri E, Gesualdo L, Schena FP and Grandaliano G: Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 352: 1317-1323, 2005.
41. Campistol JM and Schena FP: Kaposi's sarcoma in renal transplant recipients-the impact of proliferation signal inhibitors. Nephrol Dial Transplant 22(Suppl 1): i17-22, 2007.
42. Zmonarski SC, Boratynska M, Rabczynski J, Kazimierczak K and Klinger M: Regression of Kaposi's sarcoma in renal graft recipients after conversion to sirolimus treatment. Transplant Proc 37: 964-966, 2005.
43. Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, Peralba JM, Jenkins RB, Dakhil SR, Morton RF, Jaeckle KA, Scheithauer BW, Dancey J, Hidalgo M and Walsh DJ: Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 23: 5294-5304, 2005.
44. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D and Ravaud A: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372: 449-456, 2008.
45. Margolin K, Longmate J, Baratta T, Synold T, Christensen S, Weber J, Gajewski T, Quirt I and Doroshow JH: CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer 104: 1045-1048, 2005.
46. Shafer A, Zhou C, Gehrig PA, Boggess JF and Bae-Jump VL: Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis. Int J Cancer, 2009.
47. Schlosshauer PW, Li W, Lin KT, Chan JL and Wang LH: Rapamycin by itself and additively in combination with carboplatin inhibits the growth of ovarian cancer cells. Gynecol Oncol 114: 516-522, 2009.
48. Matsuzaki T, Yashiro M, Kaizaki R, Yasuda K, Doi Y, Sawada T, Ohira M and Hirakawa K: Synergistic antiproliferative effect of mTOR inhibitors in combination with 5-fluorouracil in scirrhous gastric cancer. Cancer Sci, 2009.
49. Evans JF and Kargman SL: Cancer and cyclooxygenase-2 (COX-2) inhibition. Curr Pharm Des 10: 627-634, 2004.
50. Reichle A, Vogt T, Coras B, Terheyden P, Neuber K, Trefzer U, Schultz E, Berand A, Brocker EB, Landthaler M and Andreesen R: Targeted combined anti-inflammatory and angiostatic therapy in advanced melanoma: a randomized phase II trial. Melanoma Res 17: 360-364, 2007.
51. Gadgeel SM, Wozniak A, Ruckdeschel JC, Heilbrun LK, Venkatramanamoorthy R, Chaplen RA, Kraut MJ and Kalemkerian GP: Phase II study of docetaxel and celecoxib, a cyclooxygenase-2 inhibitor, in elderly or poor performance status (PS2) patients with advanced non-small cell lung cancer. J Thorac Oncol 3: 1293-1300, 2008.
52. Sheu SY, Grabellus F, Schwertheim S, Mann K, Ensinger C, Ofner D, Bockhorn M, Fuhrer D and Schmid KW: COX-2 Expression in highly aggressive thyroid malignancies - indication for a possible therapeutic option? Horm Metab Res, 2008.
53. Waskewich C, Blumenthal RD, Li H, Stein R, Goldenberg DM and Burton J: Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res 62: 2029-2033, 2002.
54. Zhao S, Cai J, Bian H, Gui L and Zhao F: Synergistic inhibition effect of tumor growth by using celecoxib in combination with oxaliplatin. Cancer Invest 27: 636-640, 2009.
55. Kim SH, Song YC and Song YS: Celecoxib potentiates the anticancer effect of cisplatin on vulvar cancer cells independently of cyclooxygenase. Ann N Y Acad Sci 1171: 635-641, 2009.
56. Bae-Jump VL, Zhou C, Boggess JF and Gehrig PA: Synergistic effect of rapamycin and cisplatin in endometrial cancer cells. Cancer 115: 3887-3896, 2009.
57. Wang Z, Zhou J, Fan J, Qiu SJ, Yu Y, Huang XW and Tang ZY: Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. Clin Cancer Res 14: 5124-5130, 2008.
58. Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C and Abate-Shen C: Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest 118: 3051-3064, 2008.
59. Ponthan F, Wickstrom M, Gleissman H, Fuskevag OM, Segerstrom L, Sveinbjornsson B, Redfern CP, Eksborg S, Kogner P and Johnsen JI: Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo. Clin Cancer Res 13: 1036-1044, 2007.
60. Reichle A, Vogt T, Kunz-Schughart L, Bretschneider T, Bachthaler M, Brass K, Freund S and Andreesen R: Anti-inflammatory and angiostatic therapy in chemorefractory multisystem Langerhans' cell histiocytosis of adults. Br J Haematol 128: 730-732, 2005.